Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial

BACKGROUND: Early inhibition of entry and replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a very promising therapeutic approach. Polyclonal neutralizing antibodies offers many advantages such as providing immediate immunity, consequently blunting an early pro-infla...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaborit, Benjamin, Vanhove, Bernard, Vibet, Marie-Anne, Le Thuaut, Aurélie, Lacombe, Karine, Dubee, Vincent, Ader, Florence, Ferre, Virginie, Vicaut, Eric, Orain, Jéremie, Le Bras, Morgane, Omnes, Anne, Berly, Laetitia, Jobert, Alexandra, Morineau-Le Houssine, Pascale, Botturi, Karine, Josien, Régis, Flet, Laurent, Degauque, Nicolas, Brouard, Sophie, Duvaux, Odile, Poinas, Alexandra, Raffi, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7942514/
https://www.ncbi.nlm.nih.gov/pubmed/33750432
http://dx.doi.org/10.1186/s13063-021-05132-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7942514/
https://www.ncbi.nlm.nih.gov/pubmed/33750432
http://dx.doi.org/10.1186/s13063-021-05132-9

Ejemplares similares